• Explore /
  • Poster
  • / ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM).

ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM).

Abstract Video & Slides Poster

Authors

null

Constantine Si Lun Tam

Peter MacCallum Cancer Centre, Melbourne, Australia

Constantine Si Lun Tam , Ramón Garcia-Sanz , Stephen Opat , Shirley D'Sa , Wojciech Jurczak , Hui-Peng Lee , Gavin Cull , Roger G. Owen , Paula Marlton , Bjorn E. Wahlin , Alessandra Tedeschi , Jorge J. Castillo , Tanya Siddiqi , Christian Buske , Veronique Leblond , Wai Y. Chan , Jingjing Schneider , Aileen Cohen , Jane Huang , Meletios A. Dimopoulos

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT03053440

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7521)

DOI

10.1200/JCO.2022.40.16_suppl.7521

Abstract #

7521

Poster Bd #

175

Abstract Disclosures

Similar Posters

First Author: Meletios A. Dimopoulos

First Author: Javid J. Moslehi

First Author: Michael Wang

First Author: Sikander Ailawadhi